Nanoparticle-mediated gene delivery to tumour neovasculature

Trends in Molecular Medicine

Volumn 9, Issue 1, 2003, Pages 2-4

  Reynolds, Andrew R ^a   Moghimi, S Moein ^b   Hodivala Dilke, Kairbaan ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; INTEGRIN; NANOPARTICLE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

CANCER THERAPY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE THERAPY; MOUSE; NONHUMAN; REVIEW; TUMOR MODEL; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALIA;

EID: 12244313877     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)00004-7     Document Type: Short Survey

References (17)

1. Moghimi, S.M. et al. (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318
2. Hunter, A.C. and Moghimi, S.M. (2002) Therapeutic synthetic polymers: a game of Russian roulette? Drug Discov. Today 7, 998-1001
3. Hood, J.D. et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407
4. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
5. 3 for angiogenesis. Science 264, 569-571
6. Varner, J.A. and Cheresh, D.A. (1996) Integrins and cancer. Curr. Opin. Cell Biol. 8, 724-730
7. 3 antagonists promote tumour regression by inducing apoptosis in angiogenic blood vessels. Cell 79, 1157-1164
8. 5 in ocular neovascular diseases. Proc. NatlAcad. Sci. USA 93, 9764-9769
9. Hammes, H.P. et al. (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2, 529-533
10. Reynolds, L.E. et al. (2002) Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. 8, 27-34
11. Hynes, R.O. (2002) A re-evaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921
12. v β3-Clin. Cancer Res. 6, 3056-3061
13. Heidecker, G. et al. (1990) Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol. Cell. Biol. 10, 2503-2512
14. Nishikawa, M. and Huang, L. (2001) Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 12, 861-870
15. Augustin, H.G. (1998) Antiangiogenic tumour therapy: will it work? Trends Pharmacol. Sci. 19, 216-222
16. Gordon, S. et al. (1992) Antigen markers of macrophage differentiation in murine tissues. Curr. Top. Microbiol. Immunol. 181, 1-37
17. Thorin, E. and Shreeve, S.M. (1998) Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol. Ther. 78, 155-166